Comparative Pharmacology
Head-to-head clinical analysis: BISMUTH SUBCITRATE POTASSIUM METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus BRISTACYCLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISMUTH SUBCITRATE POTASSIUM METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus BRISTACYCLINE.
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE vs BRISTACYCLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bismuth subcitrate potassium forms a protective coating on gastric mucosa, binds to bile acids, and has antibacterial activity against Helicobacter pylori. Metronidazole inhibits nucleic acid synthesis by disrupting bacterial DNA, while tetracycline hydrochloride inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
BRISTACYCLINE is a tetracycline antibiotic that reversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
For Helicobacter pylori eradication: 1 tablet (bismuth subcitrate potassium 140 mg, metronidazole 125 mg, tetracycline hydrochloride 125 mg) orally 4 times daily (with meals and at bedtime) for 14 days, plus a proton pump inhibitor.
250 mg orally every 6 hours for 7-14 days.
None Documented
None Documented
Metronidazole: 8 hours (range 6-10), prolonged in hepatic impairment; Tetracycline: 6-11 hours (normal renal function), 57-120 hours in anuria; Bismuth subcitrate: negligible systemic absorption, elimination follows transit (~24-72 hours).
6-12 hours (terminal). In renal impairment, half-life extends up to 24-48 hours; dose adjustment required for CrCl <30 mL/min.
Metronidazole: 60-80% renal (as unchanged drug and metabolites), 6-15% fecal; Tetracycline: 60% renal (glomerular filtration), 40% fecal (biliary and unabsorbed); Bismuth subcitrate: >99% fecal as insoluble bismuth sulfide.
Renal (40-60% unchanged), fecal (20-30%, primarily as inactive metabolites). Biliary excretion contributes minimally (<5%).
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic